Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell Vol. 28; no. 1; p. 11
Main Authors: Kelderman, Sander, Schumacher, Ton N, Kvistborg, Pia
Format: Journal Article
Language:English
Published: United States 13.07.2015
Subjects:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
DNA Mismatch Repair
Humans
Neoplasms - drug therapy
Neoplasms - metabolism
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment - drug effects
ISSN:1878-3686, 1878-3686
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2015.06.012